Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. (Record no. 27133761)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02238 a2200649 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517152333.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201708s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1879-0852 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1016/j.ejca.2017.03.023 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Stintzing, S |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20170821 |
| 245 00 - TITLE STATEMENT | |
| Title | Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | European journal of cancer (Oxford, England : 1990) |
| Date of publication, distribution, etc. | 07 2017 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 50-60 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Randomized Controlled Trial |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Bevacizumab |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Camptothecin |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cetuximab |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Colorectal Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Exons |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Fluorouracil |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Leucovorin |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Liver Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mutation |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Proto-Oncogene Proteins B-raf |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Proto-Oncogene Proteins p21(ras) |
| General subdivision | genetics |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Retrospective Studies |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Miller-Phillips, L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Modest, D P |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fischer von Weikersthal, L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Decker, T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kiani, A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vehling-Kaiser, U |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Al-Batran, S-E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Heintges, T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kahl, C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Seipelt, G |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kullmann, F |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stauch, M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Scheithauer, W |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Held, S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Moehler, M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Jagenburg, A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kirchner, T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Jung, A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Heinemann, V |
| 773 0# - HOST ITEM ENTRY | |
| Title | European journal of cancer (Oxford, England : 1990) |
| Related parts | vol. 79 |
| -- | p. 50-60 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1016/j.ejca.2017.03.023">https://doi.org/10.1016/j.ejca.2017.03.023</a> |
| Public note | Available from publisher's website |
No items available.